GM1: Difference between revisions
No edit summary |
|||
| Line 28: | Line 28: | ||
'''GM1''' (monosialotetrahexosylganglioside) the "prototype" [[ganglioside]], is a member of the ganglio series of gangliosides which contain one [[sialic acid]] residue. GM1 has important [[physiological]] properties and impacts [[Neuroplasticity|neuronal plasticity]] and repair mechanisms, and the release of [[neurotrophins]] in the [[brain]]. Besides its function in the physiology of the brain, GM1 acts as the site of binding for both [[Cholera toxin]] and [[E. coli]] [[lability|heat-labile]] [[enterotoxin]] ([[Traveller's diarrhea]]). |
'''GM1''' (monosialotetrahexosylganglioside) the "prototype" [[ganglioside]], is a member of the ganglio series of gangliosides which contain one [[sialic acid]] residue. GM1 has important [[physiological]] properties and impacts [[Neuroplasticity|neuronal plasticity]] and repair mechanisms, and the release of [[neurotrophins]] in the [[brain]]. Besides its function in the physiology of the brain, GM1 acts as the site of binding for both [[Cholera toxin]] and [[E. coli]] [[lability|heat-labile]] [[enterotoxin]] ([[Traveller's diarrhea]]).<ref name="pmid16158191">{{cite journal | author = Mocchetti I | title = Exogenous gangliosides, neuronal plasticity and repair, and the neurotrophins | journal = Cell. Mol. Life Sci. | volume = 62 | issue = 19-20 | pages = 2283-94 | year = 2005 | pmid = 16158191 | doi = 10.1007/s00018-005-5188-y}}</ref> |
||
[[Anti-ganglioside antibodies|Antibodies to GM1]] are increased in [[Guillain-Barré syndrome]],[[dementia]] and [[lupus]] but their function is not clear. There is some evidence to suggest these antibodies are associated with [[diarrhoea]] in [[Guillain-Barré syndrome]].<ref name="pmid9313102">{{cite journal | author = Irie S, Saito T, Kanazawa N, ''et al'' | title = Relationships between anti-ganglioside antibodies and clinical characteristics of Guillain-Barré syndrome | journal = Intern. Med. | volume = 36 | issue = 9 | pages = 607-12 | year = 1997 | pmid = 9313102 | doi = }}</ref> |
[[Anti-ganglioside antibodies|Antibodies to GM1]] are increased in [[Guillain-Barré syndrome]],[[dementia]] and [[lupus]] but their function is not clear. There is some evidence to suggest these antibodies are associated with [[diarrhoea]] in [[Guillain-Barré syndrome]].<ref name="pmid9313102">{{cite journal | author = Irie S, Saito T, Kanazawa N, ''et al'' | title = Relationships between anti-ganglioside antibodies and clinical characteristics of Guillain-Barré syndrome | journal = Intern. Med. | volume = 36 | issue = 9 | pages = 607-12 | year = 1997 | pmid = 9313102 | doi = }}</ref> |
||
Revision as of 12:47, 9 September 2007
 | This article provides insufficient context for those unfamiliar with the subject. |
GM1 (monosialotetrahexosylganglioside) the "prototype" ganglioside, is a member of the ganglio series of gangliosides which contain one sialic acid residue. GM1 has important physiological properties and impacts neuronal plasticity and repair mechanisms, and the release of neurotrophins in the brain. Besides its function in the physiology of the brain, GM1 acts as the site of binding for both Cholera toxin and E. coli heat-labile enterotoxin (Traveller's diarrhea).[1]
Antibodies to GM1 are increased in Guillain-Barré syndrome,dementia and lupus but their function is not clear. There is some evidence to suggest these antibodies are associated with diarrhoea in Guillain-Barré syndrome.[2]
GM1 and the cholera toxin
The bacteria Vibrio cholerae ultimeric toxin called the cholera toxin. The A1 subunit of this toxin will gain entry to intestinal epithelial cells via the GM1 ganglioside receptor. Once inside, the A1 subunit will ADP ribosylate the Gs Alpha subunit which will prevent its GTPase activity. This will lock it in the active state and it will continuously stimulate adenylate cyclase. The sustained adenylate cyclase activity will lead to a sustained increase of cAMP which will cause electrolyte and water loss, causing diarrhea.
Fortunately, the SGLT1 receptor is present in the small intestine. When the cholera patient is given a solution containing water, sodium and glucose, the SGLT1 receptor will reabsorb sodium and glucose, while water will be passively absorbed with the sodium. This will replace the water and electrolyte loss in the cholera induced diarrhea.
References
- ^ Mocchetti I (2005). "Exogenous gangliosides, neuronal plasticity and repair, and the neurotrophins". Cell. Mol. Life Sci. 62 (19–20): 2283–94. doi:10.1007/s00018-005-5188-y. PMID 16158191.
- ^ Irie S, Saito T, Kanazawa N; et al. (1997). "Relationships between anti-ganglioside antibodies and clinical characteristics of Guillain-Barré syndrome". Intern. Med. 36 (9): 607–12. PMID 9313102.
{{cite journal}}: Explicit use of et al. in:|author=(help)CS1 maint: multiple names: authors list (link)
.svg){kind=small} | This biochemistry article is a stub. You can help Wikipedia by expanding it. |